Condition: Locally Advanced or Metastatic Pancreatic Cancer · Sponsor: BeyondBio Inc.
This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.
This description comes directly from the study's public registry record.
BeyondBio Inc. · +82-42-716-0020 · clinicaltrials@beyondbio.co.kr
Always discuss trial participation with your own doctor first.
| Yonsei University Health System Severance Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03579836